Nodus Oncology raises $2.3m to extend its seed funding

16-Jan-2024
Computer-generated image

Symbolic image

Nodus Oncology, a biotech company focused on developing first- and best-in-class molecules that inhibit novel DNA damage response (DDR) targets, announces that it has raised £1.8 million ($2.3 million) from existing investors KHAN Technology Transfer Fund I (KHAN-I) and Cumulus Oncology in an extended seed raise.

Ian Waddell, CEO of Nodus Oncology said: “This is an exciting time for Nodus Oncology; this additional investment will help us to fast-track the development of our current DDR inhibitor programmes and grow our pipeline with exciting new first-in-class assets.”

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.